VG2D Pharma Pipeline

Innovative R&D to address unmet needs in the treatment of cystic fibrosis.

Understanding the Genetic Intricacies

Cystic Fibrosis: A Complex Disease

Cystic fibrosis (CF) is a monogenic disease caused by pathogenic mutations in the CFTR gene on chromosome 7. Affecting multiple organs, its clinical manifestations vary, impacting the respiratory, reproductive, and gastrointestinal systems, as well as the mental health of patients. Despite significant progress, the management of CF still presents several challenges.

A complexe desease V1

Addressing the Gaps in the treatment of Cystic Fibrosis.

Unmet Needs

CF is the most common autosomal recessive disease among individuals of North European descent.

Despite important advancements thanks to CFTR modulators, the treatment of CF still has major unmet needs. Firstly, challenges related to access to treatment are a key problem for patients with certain genetic mutations not addressed by current drugs and for patients who cannot access treatment because of pricing.   Secondly, in view of the recency of treatments (and tritherapy in particular), the long-term quality of life during the prolonged life expectancy is still to be further documented. Similarly, more long term safety and efficacy data collection in real life clinical practice is still needed.

Pioneering Solutions for a Better Tomorrow


VG2D Pharma is committed to addressing these challenges. Our pipeline features a novel molecule with a unique mechanism of action offering significant benefits.

Broader Efficacy

Our molecules have been engineered to address types II to VI mutations, our family of leads broadens the scope of effective treatment.

Optimized Dosage

A simplified regimen of one oral tablet enhances adherence and improves patient lifestyles.

Cost Reduction

Through efficient production, we aim to expand treatment accessibility and reduce financial burdens.

Mapping Our Progress

Current Development Stages

We have finalized our preclinical proof-of-concept package and lead optimization. Here’s our current progress.

Pioneering the Future

Next steps

VG2D Pharma is gearing up for clinical trials. Stay tuned for more updates.

Trusted Sources


Dive deeper into the scientific foundations and research that inform our understanding of cystic fibrosis and our innovative approach at VG2D Pharma.

Our commitment to transparency and knowledge-sharing is rooted in science. To learn more, please consult the trusted sources below.

1. Collins FS (1992) Science 256(5058):774‐779.

2. Kerem et al. (1989) Science 245(4922):1073‐1080.

3. Bear et al. (1992) Cell 68(4):809‐818.

4. Kerem E. (2005) Pediatr Pulmonol. 40(3):183‐196.

5. De Boeck K., Amaral MD. (2016) Lancet Resp Med. 4(8):662-74.

6. Mckone et coll. (2003) Lancet 361(9370):1671‐1676.

7. Chen et al. (2021) Animal Model Exp Med. 4(3):220-232.

8. Fondation de la fibrose kystique, Comprendre les changements dans l’espérance de vie. Consulté le 8 juillet 2023.

9. McKone et al. (2021) Eur Respir J. 58(3):2002288.

10. Allen et al. (2023) Nature Communication 4:693.

11. Purkayastha et al. (2023) Journal of Cystic Fibrosis 22(3): 478-483.

12. Arooj et a’. (2023) BMJ Open Respir Res. 10(1):e001590.

Interested in learning more about VG2D Pharma and its solution ?

Request our investors’ deck or express interest in joining our team or collaborating with us.

Start A Conversation

Leave Us A Message